Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Dawson

Showing results (151-160 of 169) with videos related to

Pageof 17
Sort By:
Eclinicalmedicine|May 8, 2023
Efficacy and safety of vixotrigine in idiopathic or diabetes-associated painful small fibre neuropathy (CONVEY): a phase 2 placebo-controlled enriched-enrolment randomised withdrawal studyCatharina G Faber, Nadine Attal, Giuseppe Lauria, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 24, 2013
Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE studyLudwig Kappos, Ralf Gold, Douglas L Arnold, et al.
The New England Journal of Medicine|September 21, 2012
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosisRobert J Fox, David H Miller, J Theodore Phillips, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 8, 2000
Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestineP G Andres, P L Beck, E Mizoguchi, et al.
BMC Bioinformatics|July 14, 2019
Viral coinfection analysis using a MinHash toolkitEric T Dawson, Sarah Wagner, David Roberson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 24, 2013
Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM studyMariko Kita, Robert J Fox, J Theodore Phillips, et al.
European Journal of Cancer Care|March 19, 2003
Cancer-related fatigue--a difference of opinion? Results of a multicentre survey of healthcare professionals, patients and caregiversP Stone, E Ream, A Richardson, et al.
Annals of Clinical and Translational Neurology|March 10, 2015
Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trialsVissia Viglietta, David Miller, Amit Bar-Or, et al.
Neuropathology and Applied Neurobiology|March 14, 2018
British Neuropathological Society and International Society of Forensic Radiology and Imaging expert consensus statement for post mortem neurological imagingS C Shelmerdine, J C Hutchinson, S Al-Sarraj, et al.
The British Journal of Dermatology|May 31, 2016
Comparative transcriptome profiling provides new insights into mechanisms of androgenetic alopecia progressionE G Y Chew, B S-Y Ho, S Ramasamy, et al.
Pageof 17

Showing results (151-160 of 169) with videos related to

Sort By:
Pageof 17
Eclinicalmedicine|May 8, 2023
Efficacy and safety of vixotrigine in idiopathic or diabetes-associated painful small fibre neuropathy (CONVEY): a phase 2 placebo-controlled enriched-enrolment randomised withdrawal studyCatharina G Faber, Nadine Attal, Giuseppe Lauria, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 24, 2013
Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE studyLudwig Kappos, Ralf Gold, Douglas L Arnold, et al.
The New England Journal of Medicine|September 21, 2012
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosisRobert J Fox, David H Miller, J Theodore Phillips, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 8, 2000
Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestineP G Andres, P L Beck, E Mizoguchi, et al.
BMC Bioinformatics|July 14, 2019
Viral coinfection analysis using a MinHash toolkitEric T Dawson, Sarah Wagner, David Roberson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 24, 2013
Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM studyMariko Kita, Robert J Fox, J Theodore Phillips, et al.
European Journal of Cancer Care|March 19, 2003
Cancer-related fatigue--a difference of opinion? Results of a multicentre survey of healthcare professionals, patients and caregiversP Stone, E Ream, A Richardson, et al.
Annals of Clinical and Translational Neurology|March 10, 2015
Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trialsVissia Viglietta, David Miller, Amit Bar-Or, et al.
Neuropathology and Applied Neurobiology|March 14, 2018
British Neuropathological Society and International Society of Forensic Radiology and Imaging expert consensus statement for post mortem neurological imagingS C Shelmerdine, J C Hutchinson, S Al-Sarraj, et al.
The British Journal of Dermatology|May 31, 2016
Comparative transcriptome profiling provides new insights into mechanisms of androgenetic alopecia progressionE G Y Chew, B S-Y Ho, S Ramasamy, et al.
Pageof 17